临床剂量学模型及其在常规核医学实践中的整合路径
本文综述放射性药物治疗(RPT)与诊疗一体化框架,指出由于生物分布、摄取和滞留的变异性,已建立及新型RPT的疗效存在患者间和患者内差异。分子影像(SPECT和PET)可量化到达肿瘤和正常器官的放射性活度分数,并依据患者体型和实验室参数调整给药活度以实现个体化诊疗。文章讨论了临床在用RPT与剂量学实践及新兴RPT。
要点
- RPT疗效因生物分布、摄取和滞留的变异而存在患者间和患者内差异。
- SPECT和PET可量化到达肿瘤与正常器官的放射性活度分数。
- 可依据患者体型和实验室参数调整给药活度以优化肿瘤效应并保护正常组织。
核心结论
- 分子影像量化与个体化给药调整可支持诊疗一体化框架下的RPT剂量学实践。
研究设计与样本
- 本文为综述,讨论临床在用的RPT与剂量学实践及在晚期人类恶性肿瘤中显示治疗前景的新兴RPT。
主要发现
- RPT需全身给药,其正常器官生物分布与肿瘤组织摄取可用SPECT和PET分子影像技术映射。
- 分子影像可量化给药放射性活度(MBq)中到达肿瘤及正常器官的分数。
- 已建立和较新RPT的治疗有效性可能显示患者间和患者内变异。
关键数值与推荐
- 给药放射性活度可依据患者体型和实验室参数调整,以达到理想肿瘤效应并保护正常组织。
临床怎么用
- 在诊疗一体化框架下,可利用SPECT和PET量化生物分布,并依据患者体型和实验室参数调整给药活度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
An increasing interest in radiopharmaceutical therapy (RPT), especially in reference to the theranostic framework incorporating both diagnostic and therapeutic components have been reported. Typically, this "theranostic approach" consists of a "matching pair" of radiopharmaceuticals, comprising a diagnostic partner labelled with positron or gamma-emitting radionuclides and a therapeutic partner labelled with beta or alpha-emitting radionuclides. Due to variability in the biodistribution, uptake, and retention, the therapeutic effectiveness of established and newer radiopharmaceutical therapies may show interpatient and intrapatient variability. As RPT requires the systemic administration of radiopharmaceuticals to patients, their normal organ biodistribution, as well as uptake in tumor tissues, can be mapped using molecular imaging (SPECT and PET) techniques. This allows for the quantification of the fraction of the administered radioactivity (MBq) that reaches the tumor, as well as the normal organs. The administered radioactivity can be modified based upon a patient's body habitus and laboratory parameters to achieve the optimal and desired tumor effect and normal tissue sparing, thereby permitting delivery of an individualized theranostics. This review discusses the RPT and dosimetry practices that are in clinical use, along with other cutting-edge radiopharmaceutical therapies that have shown promising therapeutic efficacies in advanced-stage human malignancies.
引用
- Akerele M, Singh B, Mikell J, et al. Clinical Dosimetry Models and Pathway to Integration in Routine Nuclear Medicine Practice. Clin Nucl Med. 2026. PMID: 41632582. doi:10.1097/RLU.0000000000006180
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。